Paul Berg Net Worth

The estimated Net Worth of Paul Berg is at least $3.82 Million dollars as of 30 April 2007. Paul Berg owns over 7,500 units of Gilead Sciences stock worth over $1,031,985 and over the last 21 years Paul sold GILD stock worth over $2,792,740.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Berg GILD stock SEC Form 4 insiders trading

Paul has made over 23 trades of the Gilead Sciences stock since 2003, according to the Form 4 filled with the SEC. Most recently Paul exercised 7,500 units of GILD stock worth $40,575 on 30 April 2007.

The largest trade Paul's ever made was exercising 20,000 units of Gilead Sciences stock on 16 May 2005 worth over $95,600. On average, Paul trades about 1,972 units every 19 days since 2003. As of 30 April 2007 Paul still owns at least 12,750 units of Gilead Sciences stock.

You can see the complete history of Paul Berg stock trades at the bottom of the page.

What's Paul Berg's mailing address?

Paul's mailing address filed with the SEC is BECKMAN CENTER, RM. B062, STANFORD UNIVERSITY SCHOOL OF MEDICINE, STANFORD, CA, 94305.

Insiders trading at Gilead Sciences

Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger und John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.

What does Gilead Sciences do?

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Complete history of Paul Berg stock trades at Gilead Sciences

Gilead Sciences executives and stock owners

Gilead Sciences executives and other stock owners filed with the SEC include:

• Daniel O'Day,
  Chairman of the Board, Chief Executive Officer
• Johanna Mercier,
  Chief Commercial Officer
• Daniel P. O'Day,
  Chairman & CEO
• Andrew Dickinson,
  Chief Financial Officer, Executive Vice President
• Brett Pletcher,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Johanna Mercier,
  Chief Commercial Officer
• Dr. Merdad V. Parsey M.D., Ph.D.,
  Chief Medical Officer
• Merdad Parsey,
  Chief Medical Officer
• Brett A. Pletcher,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Andrew D. Dickinson,
  Exec. VP & CFO
• Per Wold-Olsen,
  Independent Director
• Richard Whitley,
  Independent Director
• Kelly Kramer,
  Independent Director
• Kevin Lofton,
  Lead Independent Director
• Harish Manwani,
  Independent Director
• Jacqueline Barton,
  Independent Director
• Sandra Horning,
  Independent Director
• Anthony Welters,
  Director
• Javier Rodriguez,
  Director
• Michael Quigley,
  Senior Vice President - Research Biology
• Linda Higgins,
  Senior Vice President - Head of External Innovation
• Jyoti Mehra,
  Executive Vice President of Human Resources
• Dr. Linda Slanec Higgins Ph.D.,
  Sr. VP & Head of External Innovation
• Jyoti K. Mehra,
  Exec. VP of HR
• Deborah H. Telman,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Dr. Diana M. Brainard M.D.,
  Sr. VP of HIV & Emerging Viral Infections
• Dr. Taiyin Yang,
  Exec. VP of Pharmaceutical Devel. & Manufacturing
• Jacquie Ross C.F.A.,
  VP of Investor Relations
• Diane E. Wilfong,
  Sr. VP, Corp. Controller & Chief Accounting Officer
• John Francis Cogan,
  Director
• John W Madigan,
  Director
• Robin L Washington,
  SVP, CFO
• Norbert W Bischofberger,
  SVP, Research
• James R Meyers,
  SVP Comm Ops North America
• Nicholas G Moore,
  Director
• Gayle E Wilson,
  Director
• Kevin Young,
  EVP, Commercial Operations
• Laura Hamill,
  EVP, Worldwide Commercial Ops
• Carla A Hills,
  Director
• Etienne Davignon,
  Director
• Paul Rutherford Carter,
  EVP Commercial Ops
• John C Martin,
  President and CEO
• John F Milligan,
  EVP, Chief Financial Officer
• John G Mc Hutchison,
  Chief Scientific Off/HeadR&D
• James M Denny,
  Director
• Gordon Earle Moore,
  Director
• Kristen Metza,
  SVP, Human Resources
• Gregg H Alton,
  SVP, General Counsel
• Paul Berg,
  Director
• Louis G Lange,
  EVP Cardiovascular Therapeutic
• Taiyin Yang,
  SVP, Pharm Dev & Mfg
• William A Lee,
  SVP Research and PPD
• Anthony Caracciolo,
  SVP
• Caroline Dorsa,
  SVP, Chief Financial Officer
• John J Toole,
  SVP
• George P Shultz,
  Director
• Alan Bruce Montgomery,
  SVP, Respiratory Therapeutics
• Michael K Inouye,
  SVP
• Mark L Perry,
  EVP Operations
• Cordell W Hull,
  Director
• Diane E. Wilfong,
  SVP, Controller & CAO
• Sandra Patterson,
  SVP, Controllership
• Jeffrey Bluestone,
  Director
• Deborah H Telman,
  EVP, Corporate Affairs & GC
• Ted W Love,
  Director